Moderna will prepare components and conduct scientific trials to collect safety and immunogenicity facts to assist FDA licensure and likely commercial scale-up in response to the long run PHE. This award will allow the rapid progress of the mRNA vaccine targeted to various influenza virus subtypes, often called strains, of https://www.amazon.com.au/gp/product/B0DCVQNHKT